



Universiteit
Leiden
The Netherlands

Systemic sclerosis: are anti-nuclear antibodies our guiding stars?

Boonstra, M.

Citation

Boonstra, M. (2022, November 8). *Systemic sclerosis: are anti-nuclear antibodies our guiding stars?*. Retrieved from <https://hdl.handle.net/1887/3485292>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3485292>

Note: To cite this publication please use the final published version (if applicable).

SYSTEMIC SCLEROSIS

are anti-nuclear antibodies our guiding stars?

Maike Boonstra

SYSTEMIC SCLEROSIS

are anti-nuclear antibodies our guiding stars?

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 8 november 2022
klokke 11:15 uur

door

Maaïke Boonstra

Printing of this thesis was financially supported by Chipsoft, NVLE fonds and Boehringer Ingelheim.w

Printing: Gildeprint Enschede, gildeprint.nl
Layout and design: Wiebke Keck, persoonlijkproefschrift.nl

Copyright 2022 © Maaïke Boonstra, The Netherlands. All rights reserved. No parts of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission of the author.

Promotor:

Prof.dr. T.W.J. Huizinga

Copromotor:

Dr. J.K. de Vries-Bouwstra

Leden Promotiecommissie:

Prof.dr. R.E.M. Toes

Prof.dr. A.H.M. van der Helm-van Mil

Prof.dr. A.E. Voskuyl (afdeling Reumatologie, Amsterdam UMC)

Dr. M.K. Ninaber

Dr. I.E.M. Bultink (afdeling reumatologie, Amsterdam UMC)

Contents

Chapter 1	General introduction	7
PART I The need for biomarker research		27
Chapter 2	Rituximab in early Systemic Sclerosis	29
PART II Auto-antibodies as biomarkers in Systemic Sclerosis		53
Chapter 3	To what extent do auto-antibodies help to identify high-risk patients in Systemic Sclerosis?	55
Chapter 4	Auto-antibodies and cancer in Systemic Sclerosis	83
PART III Anti-topoisomerase I positive Systemic Sclerosis		89
Chapter 5	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 Systemic Sclerosis criteria	91
Chapter 6	The effect of sex on outcomes in Systemic Sclerosis: does anti-topoisomerase I status matter? A EUSTAR analysis	97
Chapter 7	Association of anti-topoisomerase I antibodies of the IgM Isotype with disease progression in anti-topoisomerase I-positive Systemic Sclerosis	117
PART IV Systemic Sclerosis: are auto-antibodies our guiding stars?		135
Chapter 8	Summary and discussion	137
Chapter 9	Nederlandse samenvatting	145
Appendices		155
	Curriculum vitae	
	List of publications	
	Dankwoord	